Concurrent Radiation Therapy for Patients with Metastatic Melanoma and Receiving Anti-Programmed-Death 1 Therapy: A Retrospective Monocentric Study on 141 Patients

Abstract

cm) failed at 5 months, and one lesion (3.9 cm) recurred 21 months after SBRT. Two of the 3 patients with LF received SBRT as salvage after failing metastatectomy at the same site. In the entire cohort, local control and OS did not differ based on age, gender, histology, fractionation regimen, lesion location, or size (all p>0.05). Three patients developed grade 2 chest wall toxicities; one patient had grade 2 pneumonitis. No other acute or late grade 2 toxicities were observed. Conclusion: To our knowledge, this is the first multi-institutional series reporting on SBRT for pulmonary sarcoma metastases and demonstrates that SBRT is well-tolerated with excellent local control. SBRT should be considered in these patients as an alternative to surgical resection. Prospective trials of SBRT vs. surgery are warranted.